Article
Multidisciplinary Sciences
Syamel Muhammad, Reyhan Julio Azwan, Rauza Sukma Rita, Restu Susanti, Yusrawati
Summary: This study investigates the predictive role of IL6, CA-125, and HE4 in tumor resectability in pre-operative patients with advanced epithelial ovarian cancer and finds a correlation between these markers and tumor resectability.
Article
Oncology
Koceila Amroun, Raphael Chaltiel, Fabien Reyal, Reza Kianmanesh, Aude-Marie Savoye, Marine Perrier, Zoubir Djerada, Olivier Bouche
Summary: Using a joint model (JM) of longitudinal CA-125 level during neoadjuvant chemotherapy (NAC) is a reliable predictor of complete interval cytoreductive surgery (ICRS) feasibility in patients with advanced ovarian cancer (AOC), helping to avoid unnecessary laparotomy.
Article
Oncology
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Helene Costaz, Manuel Rodrigues, Isabelle Ray-Coquard, Laurence Gladieff, Roman Rouzier, Thibault De La Motte Rouge, Sebastien Gouy, Emmanuel Barranger, Renaud Sabatier, Anne Floquet, Frederic Marchal, Cecile Guillemet, Valentine Polivka, Anne-Laure Martin, Pierre-Emmanuel Colombo, Frederic Fiteni
Summary: Interval debulking surgery after 3-4 cycles of neoadjuvant chemotherapy can improve survival for patients with epithelial ovarian cancer who are not able to receive upfront complete debulking surgery. However, performing debulking surgery after ≥5 cycles of neoadjuvant chemotherapy may have a negative effect on patient survival.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Augusto Pereira, Javier F. Magrina, Paul M. Magtibay, Joao Siufi Neto, Daniela F. S. Siufi, Yu-Hui H. Chang, Tirso Perez-Medina
Summary: Minimally invasive surgery can be used for interval debulking after neoadjuvant chemotherapy in selected patients with initially unresectable ovarian cancer. It has the main benefits of shorter hospital stay and fewer intestinal resections compared to primary debulking. Neoadjuvant chemotherapy allows a minimally invasive approach for interval debulking in patients with ovarian cancer considered unresectable at diagnosis.
Article
Chemistry, Multidisciplinary
Julian Matthias Metzler, Daniel Fink, Patrick Imesch
Summary: Ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase, is used to treat hematological diseases like chronic lymphocytic leukemia. The hypothesis that it may suppress the tumor marker CA-125 in ovarian cancer is based on an observation in a patient with low-grade serous ovarian cancer who received ibrutinib for CLL. A mechanistic model explaining this potential drug effect is proposed for further research.
APPLIED SCIENCES-BASEL
(2021)
Article
Oncology
Eva K. Egger, Marie Antonia Buchen, Florian Recker, Matthias B. Stope, Holger Strunk, Alexander Mustea, Milka Marinova
Summary: The study aimed to identify preoperative CT scan markers that predict incomplete cytoreduction in ovarian cancer patients. The results showed that large-volume ascites, absence of numerically increased small lymph nodes at the mesenteric root, and carcinomatosis of the transverse colon are markers predictive of incomplete cytoreduction.
FRONTIERS IN ONCOLOGY
(2022)
Review
Surgery
Yong Jung Song
Summary: The main management of advanced ovarian cancer is maximal cytoreductive surgery followed by chemotherapy. Alternative treatments include neoadjuvant chemotherapy and interval debulking surgery for patients who are not suitable for maximal cytoreductive surgery. Predicting optimal debulking before treatment is crucial for the successful management of ovarian cancer, with various biomarkers and imaging studies being used for this purpose.
Article
Oncology
Ryan M. Kahn, Erin McMinn, Effi Yeoshoua, Thomas Boerner, Qin Zhou, Alexia Iasonos, Kara Long Roche, Oliver Zivanovic, Ginger J. Gardner, Yukio Sonoda, Roisin E. O'Cearbhaill, Rachel N. Grisham, William Tew, David Jones, James Huang, Bernard J. Park, Nadeem R. Abu-Rustum, Dennis S. Chi
Summary: This study investigated the feasibility, safety, and survival outcomes of intrathoracic cytoreduction during primary debulking surgery for advanced ovarian cancer. The results showed that intrathoracic cytoreduction is both safe and feasible, and can significantly improve patients' progression-free survival (PFS) and overall survival (OS).
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Alli M. Straubhar, Jennifer L. Wolf, Qin C. Zhou, Alexia Iasonos, Stephanie Cham, Jason D. Wright, Kara Long Roche, Dennis S. Chi, Oliver Zivanovic
Summary: This study validated a complication nomogram at a high-volume surgical center, which effectively predicts a lower likelihood of serious postoperative complications in patients with epithelial ovarian cancer undergoing debulking surgery. An enhanced nomogram would help identify patients at higher risk for serious complications.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Health Care Sciences & Services
Alexandros Laios, Evangelos Kalampokis, Racheal Johnson, Amudha Thangavelu, Constantine Tarabanis, David Nugent, Diederick De Jong
Summary: This study developed an AI-based predictive model for the outcome of R0 resection in patients with epithelial ovarian cancer. The model showed high accuracy and provided feature explainability. Factors that increased the probability of complete cytoreduction were identified, which can be used for quality control and internal audit purposes.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Eleni Karamouza, Rosalind M. M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cecile Proust-Lima, Xavier Paoletti
Summary: Cancer antigen 125 (CA-125) is a protein that is present in high concentrations in the blood of patients with specific types of cancer, especially ovarian cancer. This study compared different ways of summarizing CA-125 levels during the first 3 to 6 months of treatment for advanced ovarian cancer, and evaluated their ability to predict overall survival. The results showed that measuring CA-125 levels at 3 months and estimating its decline provided the best prediction of overall survival in these patients.
Article
Oncology
Nicholas Cardillo, Eric J. Devor, Silvana Pedra Nobre, Andreea Newtson, Kimberly Leslie, David P. Bender, Brian J. Smith, Michael J. Goodheart, Jesus Gonzalez-Bosquet
Summary: This study aimed to improve the surgical outcomes and survival of ovarian cancer patients by using tumor genomics to create prediction models. By utilizing a large biobank of ovarian cancer tumors and statistical learning methods, multiple predictive models were successfully developed. Some of these models showed potential to outperform clinical decision-making. Prospective validation of these models could enhance the ability to predict surgical outcomes in ovarian cancer.
Article
Oncology
Nicole D. Fleming, Shannon N. Westin, Larissa A. Meyer, Aaron Shafer, Jose Alejandro Rauh-Hain, Michaela Onstad, Lauren Cobb, Michael Bevers, Bryan M. Fellman, Jennifer Burzawa, Priya Bhosale, Behrouz Zand, Amir Jazaeri, Charles Levenback, Robert L. Coleman, Pamela T. Soliman, Anil K. Sood
Summary: The study found a low correlation between surgeon radiology review and actual laparoscopic scoring assessment in patients with advanced stage ovarian cancer, highlighting the limited accuracy of surgeon radiographic assessment in determining resectability.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Er Yue, Guangchao Yang, Yuanfei Yao, Guangyu Wang, Atish Mohanty, Fang Fan, Ling Zhao, Yanqiao Zhang, Tamara Mirzapoiazova, Tonya C. Walser, Lorna Rodriguez-Rodriguez, Yuman Fong, Ravi Salgia, Edward Wenge Wang
Summary: Ovarian cancer is a deadly disease with urgent need for new treatments. The development of a conditionally replicative oncolytic adenovirus (CRAd) that targets MUC16/CA-125 in cancer cells shows promising anti-cancer effects. This approach represents a unique and practical direction for further investigation in ovarian cancer treatment.
Article
Oncology
Sabrina Piedimonte, Marcus Q. Bernardini, Taymaa May, Paulina Cybulska, Sarah E. Ferguson, Stephane Laframboise, Genevieve Bouchard-Fortier, Lisa Avery, Liat Hogen
Summary: For patients aged 70 and above with advanced epithelial ovarian cancer, surgery should not be deferred solely based on age. Fit patients aged 70 and above may benefit from primary cytoreductive surgery (PCS), while those aged 80 and above may benefit from neoadjuvant chemotherapy (NACT) over PCS.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Nadine Rayes, Deborah J. Bowen, Tara Coffin, Denise Nebgen, Christine Peterson, Mark F. Munsell, Kathleen Gavin, Rebecca Lechner, Jamie Crase, Deborah Polinsky, Iris Romero, Stephanie V. Blank, Douglas A. Levine, Barbara M. Norquist, Elizabeth M. Swisher, Karen H. Lu
Article
Biochemistry & Molecular Biology
Yongchao Dou, Emily A. Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang, Lili Blumenberg, Alla Karpova, Vladislav A. Petyuk, Sara R. Savage, Shankha Satpathy, Wenke Liu, Yige Wu, Chia-Feng Tsai, Bo Wen, Zhi Li, Song Cao, Jamie Moon, Zhiao Shi, MacIntosh Cornwell, Matthew A. Wyczalkowski, Rosalie K. Chu, Suhas Vasaikar, Hua Zhou, Qingsong Gao, Ronald J. Moore, Kai Li, Sunantha Sethuraman, Matthew E. Monroe, Rui Zhao, David Heiman, Karsten Krug, Karl Clauser, Ramani Kothadia, Yosef Maruvka, Alexander R. Pico, Amanda E. Oliphant, Emily L. Hoskins, Samuel L. Pugh, Sean J. I. Beecroft, David W. Adams, Jonathan C. Jarman, Andy Kong, Hui-Yin Chang, Boris Reva, Yuxing Liao, Dmitry Rykunov, Antonio Colaprico, Xi Steven Chen, Andrzej Czekanski, Marcin Jedryka, Rafa Matkowski, Maciej Wiznerowicz, Tara Hiltke, Emily Boja, Christopher R. Kinsinger, Mehdi Mesri, Ana I. Robles, Henry Rodriguez, David Mutch, Katherine Fuh, Matthew J. Ellis, Deborah DeLair, Mathangi Thiagarajan, D. R. Mani, Gad Getz, Michael Noble, Alexey I. Nesvizhskii, Pei Wang, Matthew L. Anderson, Douglas A. Levine, Richard D. Smith, Samuel H. Payne, Kelly V. Ruggles, Karin D. Rodland, Li Ding, Bing Zhang, Tao Liu, David Fenyo
Article
Oncology
Melissa K. Frey, Sarah S. Lee, Deanna Gerber, Zachary P. Schwartz, Jessica Martineau, Kathleen Lutz, Erin Reese, Emily Dalton, Annie Olsen, Julia Girdler, Bhavana Pothuri, Leslie Boyd, John P. Curtin, Douglas A. Levine, Stephanie Blank
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Panagiotis A. Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N. Grisham, Paul J. Goodfellow, Elise C. Kohn, Douglas A. Levine, Joyce F. Liu, Karen H. Lu, Dorinda Sparacio, Christina M. Annunziata
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
J. Millstein, T. Budden, E. L. Goode, M. S. Anglesio, A. Talhouk, M. P. Intermaggio, H. S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R. C. Bentley, C. Wang, D. S. Chiu, S. Kommoss, S. C. Y. Leung, J. Senz, A. Lum, V Chow, H. Sudderuddin, R. Mackenzie, J. George, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Kobel, I. A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramon y Cajal, J. Garcia-Donas, S. Hernando Polo, G. C. Rodriguez, K. L. Cushing-Haugen, H. R. Harris, C. S. Greene, R. A. Zelaya, S. Behrens, R. T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubinski, O. Oszurek, A. Toloczko, C. Cybulski, J. Menkiszak, C. L. Pearce, M. C. Pike, C. Tseng, J. Alsop, V Rhenius, H. Song, M. Jimenez-Linan, A. M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C. J. Kennedy, R. Sharma, P. R. Harnett, B. Gao, S. E. Johnatty, R. Sayer, J. Boros, S. J. Winham, G. L. Keeney, S. H. Kaufmann, M. C. Larson, H. Luk, B. Y. Hernandez, P. J. Thompson, L. R. Wilkens, M. E. Carney, B. Trabert, J. Lissowska, L. Brinton, M. E. Sherman, C. Bodelon, S. Hinsley, L. A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A. H. Wu, U. Menon, M. T. Goodman, J. M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. DeFazio, S. A. Gayther, M. J. Garcia, M. J. Henderson, M. A. Rossing, A. Beeghly-Fadiel, P. A. Fasching, S. Orsulic, B. Y. Karlan, G. E. Konecny, D. G. Huntsman, D. D. Bowtell, J. D. Brenton, J. A. Doherty, P. D. P. Pharoah, S. J. Ramus
ANNALS OF ONCOLOGY
(2020)
Review
Oncology
Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P. D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, Bernard E. Weissman
CLINICAL CANCER RESEARCH
(2020)
Editorial Material
Multidisciplinary Sciences
Victoria L. Bae-Jump, Douglas A. Levine
Article
Genetics & Heredity
Honglin Song, Ed M. Dicks, Jonathan Tyrer, Maria Intermaggio, Georgia Chenevix-Trench, David D. Bowtell, Nadia Traficante, James Brenton, Teodora Goranova, Karen Hosking, Anna Piskorz, Elke van Oudenhove, Jen Doherty, Holly R. Harris, Mary Anne Rossing, Matthias Duerst, Thilo Dork, Natalia Bogdanova, Francesmary Modugno, Kirsten Moysich, Kunle Odunsi, Roberta Ness, Beth Y. Karlan, Jenny Lester, Allan Jensen, Susanne Kruger Kjaer, Estrid Hogdall, Ian G. Campbell, Conxi Lazaro, Miguel Angel Pujara, Julie Cunningham, Robert Vierkant, Stacey J. Winham, Michelle Hildebrandt, Chad Huff, Donghui Li, Xifeng Wu, Yao Yu, Jennifer B. Permuth, Douglas A. Levine, Joellen M. Schildkraut, Marjorie J. Riggan, Andrew Berchuck, Penelope M. Webb, Cezary Cybulski, Jacek Gronwald, Anna Jakubowska, Jan Lubinski, Jennifer Alsop, Patricia Harrington, Isaac Chan, Usha Menon, Celeste L. Pearce, Anna H. Wu, Anna de Fazio, Catherine J. Kennedy, Ellen Goode, Susan Ramus, Simon Gayther, Paul Pharoah
Summary: This study aimed to investigate the contribution of rare deleterious germline variants in candidate genes to ovarian cancer susceptibility. The findings suggest a potential association between PALB2 mutations and increased risk of high-grade serous ovarian cancer, with further research needed to confirm the significance of other genes.
JOURNAL OF MEDICAL GENETICS
(2021)
Article
Oncology
Alexander Shushkevich, Premal H. Thaker, Ramey D. Littell, Naishadh A. Shah, Sarah Chiang, Katherine Thornton, Martee L. Hensley, Brian M. Slomovitz, Kevin M. Holcomb, Mario M. Leitao, Michael D. Toboni, Matthew A. Powell, Douglas A. Levine, Sean C. Dowdy, Ann Klopp, Jubilee Brown
GYNECOLOGIC ONCOLOGY
(2020)
Review
Oncology
Amnon A. Berger, Fanny Dao, Douglas A. Levine
Summary: Endometrial carcinoma is the most common gynecologic malignancy in the modern world, with limited therapeutic options. Researchers have been trying to identify prognostic and therapeutic biomarkers, with recent trials shedding new light on possible treatment strategies.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Harini Veeraraghavan, Herbert Alberto Vargas, Sanchez Alejandro-Jimenez, Maura Micco, Eralda Mema, Yulia Lakhman, Mireia Crispin-Ortuzar, Erich P. Huang, Douglas A. Levine, Rachel N. Grisham, Nadeem Abu-Rustum, Joseph O. Deasy, Alexandra Snyder, Martin L. Miller, James D. Brenton, Evis Sala
Article
Oncology
Kimberly K. Leslie, Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, David Mutch, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Yovanni Casablanca, Amanda Jackson, Peter G. Rose, XunClare Zhou, Michael McHale, Heather Lankes, Douglas A. Levine, Carol Aghajanian
Summary: The study suggests that mutations in the TP53 gene are associated with improved progression-free survival (PFS) and overall survival (OS) in advanced endometrial cancer patients receiving bevacizumab, compared to temsirolimus. This indicates that TP53 mutational status may serve as a potential biomarker for guiding treatment choices in endometrial cancer patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Endometrial cancers with pathogenic POLE mutations are not associated with traditional risk parameters, and patients do not seem to benefit from adjuvant therapy. Low rates of recurrence/progression and high salvage rates may allow for safely decreasing treatment intensity for these patients.
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Patients with ECs harboring pathogenic POLE mutations do not benefit from adjuvant therapy, as these mutations are not associated with most traditional risk parameters, and they exhibit low rates of adverse events with high and sustained salvage rates in cases of recurrence.
Article
Oncology
Shuang Zhang, Sonia Iyer, Hao Ran, Igor Dolgalev, Shengqing Gu, Wei Wei, Connor J. R. Foster, Cynthia A. Loomis, Narciso Olvera, Fanny Dao, Douglas A. Levine, Robert A. Weinberg, Benjamin G. Neel
Summary: Genetically informed, immunocompetent tumor models are crucial for evaluating conventional, targeted, and immune therapies. By engineering mouse fallopian tube organoids, researchers were able to study the effects of specific mutations found in high-grade serous tubo-ovarian cancer (HGSC) models, leading to the development of effective combination treatments for different genetic subgroups of HGSC. These findings highlight the importance of genotype-informed, syngeneic organoid models for understanding tumor biology and therapeutic responses.